The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Simulect
basiliximab · BASILIXIMAB 10 mg/2.5mL · Injection, Powder, For Solution · Intravenous · Novartis Pharmaceuticals Corporation
NDC 00078-0393-61 · 1 VIAL, SINGLE-USE in 1 CARTON / 2.5 mL in 1 VIAL, SINGLE-USE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$3,543.13
Reported to Texas DSHS · 2026 annual filing · Novartis Pharmaceuticals Corporation
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 20 MG
$4905.049
HCPCS J0480 · Jul 1, 2026 quarter · typically ASP + 6%
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA103764
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of basiliximab (Injection, Powder, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Novartis Pharma Stein AG | BASILIXIMAB 10 mg/2.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Novartis Pharmaceuticals Corporation | BASILIXIMAB 10 mg/2.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Novartis Pharmaceuticals Corporation | BASILIXIMAB 20 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Patheon Italia S.p.A. | BASILIXIMAB 10 mg/2.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Patheon Italia S.p.A. | BASILIXIMAB 20 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Simulect — NDC 00078-0393-61," retrieved September 3, 2026, https://drugdashboards.com/drug/00078039361.
Free to cite with attribution — see how the data is put together.